Shareholders That Lost Money on Caribou Biosciences, Inc. (CRBU) Should Contact Levi & Korsinsky About Pending Class Action - CRBU ...

CRBU INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Caribou Biosciences, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! ...

NEW YORK, Jan. 17, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Caribou Biosciences, Inc. ("Caribou Biosciences, Inc." or the "Company") (NASDAQ: CRBU) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Caribou Biosciences, Inc. investors who were adversely affected by alleged securities fraud between July 14, 2023 and July 16, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/ ...

Levi & Korsinsky Notifies Caribou Biosciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - CRBU ...

CRBU LAWSUIT ALERT: Levi & Korsinsky Notifies Caribou Biosciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline ...

NEW YORK, Jan. 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU).Shareholders who purchased shares of CRBU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/caribou-biosciences-inc-loss-submission-form/?id=123056&from=4CLASS PERIOD: Jul ...

NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU). Shareholders who purchased shares of CRBU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/caribou-biosciences-inc-loss-submission-form/?id=122791&from=3 CLASS PER ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Caribou To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in Caribou between July 14, 2023 and July 16, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Jan. 15, 2025 /PRNewswire/ -- ...

NEW YORK, Jan. 14, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Caribou Biosciences, Inc. ("Caribou Biosciences, Inc." or the "Company") (NASDAQ: CRBU) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Caribou Biosciences, Inc. investors who were adversely affected by alleged securities fraud between July 14, 2023 and July 16, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/ ...

Company Overview - Caribou Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for treating hematologic malignancies in the US and internationally [3] Financial and Operational Developments - On July 16 2024 Caribou disclosed in an SEC filing that it discontinued preclinical research activities associated with its allogeneic CAR-NK platform and reduced its workforce by 21 positions or approximately 12% to extend its cash runway [1] - Following this announcement Caribou's stock price fell 33% to close at $264 per share on July 17 2024 [1] Clinical Trial and Product Updates - On June 2 2024 Caribou issued a press release announcing updated clinical data from the ongoing ANTLER Phase 1 trial indicating that a single dose of CB-010 has the potential to rival the safety efficacy and durability of approved autologous CAR-T cell therapies [6] - In response to this announcement Evercore ISI analysts downgraded Caribou stock to "in line" and dropped their price target to $300 from $1300 [6] - Caribou's stock price fell 2552% to close at $2145 per share on June 3 2024 following the announcement [6] Legal and Regulatory Matters - A class action lawsuit was filed on behalf of all persons and entities that purchased or otherwise acquired Caribou Biosciences Inc securities between July 14 2023 and July 16 2024 [3] - The complaint alleges that Caribou misled investors regarding the efficacy of its lead drug candidate CB-010 overstating its safety efficacy and durability relative to approved autologous CAR-T cell therapies [4] - The complaint also alleges that Caribou failed to disclose significant risks of insufficient cash liquidity and capital to fund its current business operations including preclinical research activities associated with the allogeneic CAR-NK platform [4] - Shareholders who want to serve as lead plaintiff for the class must submit their application to the court by February 24 2025 [5]